This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SURF Surface Oncology (SURF) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Surface Oncology Stock (NASDAQ:SURF) 30 days 90 days 365 days Advanced Chart Get Surface Oncology alerts:Sign Up Key Stats Today's Range$1.07▼$1.0750-Day Range$0.88▼$1.0852-Week Range$0.56▼$1.43VolumeN/AAverage Volume430,375 shsMarket Capitalization$65.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc. Read More Receive SURF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surface Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SURF Stock News HeadlinesMethod AI raises $20m to advance robotic surgery assistance technologyAugust 23, 2025 | msn.comHepatocellular Carcinoma Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightMay 7, 2025 | theglobeandmail.comReagan’s former tech advisor sharing bombshell announcementGeorge Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.September 16 at 2:00 AM | Banyan Hill Publishing (Ad)International conference at the Thangam Cancer Center - Experts delivering edging Tech in Medical field at NamakkalJanuary 25, 2025 | msn.comCan estrogen cream combat skin aging signs? Here’s what dermatologists say.November 14, 2024 | washingtonpost.com‘Tremendous potential’: Cell therapy shows promise in treating deadly brain cancer in new trialNovember 14, 2024 | msn.comCAR-T therapy offers hope against an incurable brain tumor: patient shows no sign of disease after four yearsNovember 14, 2024 | msn.comTreatment offers promise for 'terrible, terrible' brain cancer in young peopleNovember 14, 2024 | msn.comSee More Headlines SURF Stock Analysis - Frequently Asked Questions How were Surface Oncology's earnings last quarter? Surface Oncology, Inc. (NASDAQ:SURF) released its earnings results on Thursday, November, 4th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.40) by $0.04. The company earned $0.39 million during the quarter. When did Surface Oncology IPO? Surface Oncology (SURF) raised $84 million in an initial public offering on Thursday, April 19th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI acted as the underwriters for the IPO. What other stocks do shareholders of Surface Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Surface Oncology investors own include Meta Platforms (META), NVIDIA (NVDA), CrowdStrike (CRWD), NIO (NIO), Zoom Communications (ZM), QUALCOMM (QCOM) and Workhorse Group (WKHS). Company Calendar Last Earnings11/04/2021Today9/16/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:SURF CIK1718108 Webwww.surfaceoncology.com Phone(617) 714-4096FaxN/AEmployees35Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$63.59 million Net MarginsN/A Pretax Margin-211.95% Return on Equity-107.81% Return on Assets-65.57% Debt Debt-to-Equity RatioN/A Current Ratio3.60 Quick Ratio3.60 Sales & Book Value Annual Sales$30 million Price / Sales2.17 Cash FlowN/A Price / Cash FlowN/A Book Value$0.81 per share Price / Book1.32Miscellaneous Outstanding Shares60,824,000Free Float53,525,000Market Cap$65.08 million OptionableNot Optionable Beta1.75 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:SURF) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored$4?In times like these… it’s almost impossible to find a good deal. That’s why you should check this out. G...Monument Traders Alliance | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surface Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Surface Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.